| Literature DB >> 32664504 |
Vladimir P Berishvili1, Alexander N Kuimov2, Andrew E Voronkov1,3, Eugene V Radchenko1, Pradeep Kumar4, Yahya E Choonara4, Viness Pillay4, Ahmed Kamal5, Vladimir A Palyulin1.
Abstract
Tankyrase enzymes (TNKS), a core part of the canonical Wnt pathway, are a promising target in the search for potential anti-cancer agents. Although several hundreds of the TNKS inhibitors are currently known, identification of their novel chemotypes attracts considerable interest. In this study, the molecular docking and machine learning-based virtual screening techniques combined with the physico-chemical and ADMET (absorption, distribution, metabolism, excretion, toxicity) profile prediction and molecular dynamics simulations were applied to a subset of the ZINC database containing about 1.7 M commercially available compounds. Out of seven candidate compounds biologically evaluated in vitro for their inhibition of the TNKS2 enzyme using immunochemical assay, two compounds have shown a decent level of inhibitory activity with the IC50 values of less than 10 nM and 10 μM. Relatively simple scores based on molecular docking or MM-PBSA (molecular mechanics, Poisson-Boltzmann, surface area) methods proved unsuitable for predicting the effect of structural modification or for accurate ranking of the compounds based on their binding energies. On the other hand, the molecular dynamics simulations and Free Energy Perturbation (FEP) calculations allowed us to further decipher the structure-activity relationships and retrospectively analyze the docking-based virtual screening performance. This approach can be applied at the subsequent lead optimization stages.Entities:
Keywords: MM-PBSA; free energy perturbation; immunochemical assay; molecular docking; molecular dynamics; tankyrase inhibitors
Mesh:
Substances:
Year: 2020 PMID: 32664504 PMCID: PMC7397142 DOI: 10.3390/molecules25143171
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Compounds A1–A7 selected by virtual screening from the subset of the ZINC database.
Figure 2Initial screening results of potential tankyrase inhibitors. Dot blot reflects the amount of the poly-ADP-ribose product of the PARP enzymatic reaction. Positions A1 and B1—tankyrase in the absence of inhibitors; C1 and D1—tankyrase with a positive control inhibitor XAV939, no product; A5 and D5—PARP1 as positive control. Compounds A1–A7 are applied respectively at positions A2 and B2, C2 and D2, A3 and B3, C3 and D3, A4 and B4, C4 and D4, B5 and C5.
Figure A1Concentration-response curves for compounds A1 (A) and A3 (B).
Parameters of the Concentration-Response Curves for Compounds A1 and A3.
| Compound |
|
|
|
|
|---|---|---|---|---|
| A1 | 8.5 ± 0.2 | 17.1 ± 0.2 | 3.1 ± 0.5 nM | 0.8 ± 0.1 |
| A3 | 4 ± 2 | 25 ± 3 | 4 ± 2 μM | 1.2 ± 0.6 |
Predicted binding affinities/scores and standard deviations for compounds A1–A7.
| Compound | Binding Affinity Predicted by Docking Scoring Function, kcal/mol | Binding Probability Predicted by ML Scoring Function | Binding Energy Calculated by MM-PBSA, kcal/mol |
|---|---|---|---|
| A1 | −12.8 ± 0.1 | 0.61 ± 0.1 | −32.5 ± 10.3 |
| A2 | −12.4 ± 0.2 | 0.70 ± 0.1 | −36.3 ± 9.8 |
| A3 | −12.4 ± 0.1 | 0.62 ± 0.1 | −30.8 ± 9.2 |
| A4 | −11.7 ± 0.1 | 0.24 ± 0.1 | −28.1 ± 9.6 |
| A5 | −12.6 ± 0.2 | 0.15 ± 0.1 | −29.1 ± 9.7 |
| A6 | −12.5 ± 0.1 | 0.46 ± 0.1 | −31.2 ± 8.0 |
| A7 | −12.6 ± 0.1 | 0.56 ± 0.1 | −32.0 ± 8.8 |
Figure 3Binding modes of compounds A1 (A) and A3 (B) predicted by molecular docking and molecular dynamics. The ligand molecule is represented by grey ball-and-stick model. The amino acid residues located within 4 Å from it are shown as beige stick models. Hydrogen bonds are shown by cyan lines.
Figure 4RMSD values from the initial coordinates for compounds A1 and A3 in the protein-ligand complexes.
Free energy differences calculated for each stage of the alchemical thermodynamic cycle for compounds A1, A2, A3, A7.
| Binding Free Energy (kcal/mol) | A1 | A2 a | A3 a | A7 a | |
|---|---|---|---|---|---|
|
|
|
|
|
|
|
| Coulomb term |
| −30.2 ±0.1 | −15.9 ± 0.1 (14.3) | −20.6 ± 0.1 (9.6) | −22.1 ± 0.1 (8.1) |
| van der Waals andrestraint term |
| −19.3 ± 0.1 | −19.3 ± 0.2 (0.0) | −12.3 ± 0.1 (7.0) | −17.3 ± 0.1 (2.0) |
|
|
|
|
|
|
|
| Coulomb term |
| 29.5 ± 0.1 | 18.1 ± 0.1 (−11.4) | 21.5 ± 0.1 (−8.0) | 37.1 ± 0.1 (7.6) |
| van der Waals term |
| 1.9 ± 0.1 | 2.2 ± 0.1 (0.3) | 0.5 ± 0.1 (−1.4) | 3.1 ± 0.1 (1.2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note:a values relative to the compound A1 are listed in parentheses.
Predicted Physicochemical and ADMET Profiles of Compounds Selected by Virtual Screening.
| Compound | MW | LogPow | pS | LogBB | HIA | hERG p | hERG pIC50 |
|---|---|---|---|---|---|---|---|
| A1 | 414.42 | 1.98 | 4.35 | 0.53 | 100.0 | 4.26 | 4.00 |
| A2 | 436.48 | 2.57 | 4.72 | −0.60 | 100.0 | 5.04 | 5.03 |
| A3 | 416.43 | 3.33 | 4.94 | −0.46 | 90.8 | 5.65 | 4.50 |
| A4 | 394.44 | 2.76 | 4.23 | −1.23 | 100.0 | 5.49 | 5.63 |
| A5 | 401.43 | 3.10 | 4.05 | 1.52 | 93.0 | 4.86 | 4.65 |
| A6 | 305.30 | 2.38 | 3.71 | 0.20 | 87.5 | 4.04 | 4.66 |
| A7 | 429.39 | 2.23 | 4.42 | −1.10 | 97.6 | 5.05 | 5.92 |
Note: MW—molecular weight, LogPow—octanol-water partition coefficient, pS—aqueous solubility [−log(M)], LogBB—blood-brain barrier permeability, HIA—human intestinal absorption [%], hERG pK—hERG potassium channel affinity [−log(M)], hERG pIC50—hERG potassium channel inhibitory activity [−log(M)].